menu
    • menu

    Looking for excipients offered by Kewpie Corporation? Find information on Kewpie Corporation's regulatory filings (DMFs), cGMP inspections, pricing availability, etc. on PharmaCompass.

    Kewpie-PSE
    News
    Notice of the Progress of Acquisition by Company of its Own Share

    02 Dec 2025

    // PRESS RELEASE

    Notice of Purchase of Fractional Shares by the Company

    27 Nov 2025

    // PRESS RELEASE

    Notice regarding Revision of the Forecasts FY Ending Nov 30 2025

    02 Oct 2025

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Kewpie Corporation

    Contact Supplier

    Website

    CPhI Japan

    Exhibiting

    Book a meeting

    envelop Contact Supplier

    Latest Content

    https://www.youtube.com/embed/a9474wUfYEQ

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    Key Products KEY PRODUCTS

    EXCIPIENTS

    EXCIPIENTS BY INGREDIENTS

    EXCIPIENTS BY APPLICATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Related CompaniesRelated Companies

    About

    Kewpie, the leading Japanese manufacturer of pharmaceutical-grade Sodium hyaluronate, first developed it in 1983. Its products are used as APIs and excipients for injections, eye drops, and external preparations, manufactured near Tokyo under strict regulations. Since 2016, Kewpie also produces medical devices using Sodium hyaluronate and offers derivatives as per client needs. Kewpie exports to over 30 countries. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Kewpie Corporationjapan Flag
    Country
    Country
    Japan
    Address
    Address
    1-4-13, Shibuya, Shibuya-Ku, Tokyo 150-0002
    Telephone
    Telephone
    +81 8084590388
    Client Email
    Email
    makoto_onodera@kewpie.co.jp
    Client Website
    Website
    https://www.kewpie.com/en/finechemical/medical/sodium-hyaluronate/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/kewpie-fine-chemical/
    youtube
    YouTube
    http://www.youtube.com/@kewpiefinechemicalsdivisio501
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/kewpie-corporation-party-content-552.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/kewpie-corporation-party-content-16624.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Functional Hyaluronic Acids

    read-more

      https://www.pharmacompass.com/pdf/party/content/kewpie-corporation-party-content-40787.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    HYALO-OLIGO

    read-more

      https://www.pharmacompass.com/pdf/party/content/kewpie-corporation-party-content-99745.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Hyabest

    read-more

      https://www.pharmacompass.com/pdf/party/content/kewpie-corporation-party-content-60058.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Hyaloevil-P

    read-more

      https://www.pharmacompass.com/pdf/party/content/kewpie-corporation-party-content-56320.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Hyalorepair

    read-more

      https://www.pharmacompass.com/pdf/party/content/kewpie-corporation-party-content-55693.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    New Cross-linked Hyaluronic Acid

    read-more

      https://www.pharmacompass.com/pdf/party/content/kewpie-corporation-party-content-41354.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    Excipient Market Overview: Evonik launches high-purity excipients; India mandates disclosures from March 2026

    Excipient Market Overview: Evonik launches high-purity excipients; India mandates disclosures from March 2026

    The global pharmaceutical excipients market continued to evolve in the third quarter (Q3) of 2025, supported by rising demand for functional excipients, growth in production of generics, and advances in drug delivery technologies. The global market for pharmaceutical excipients was estimated at US$ 9.8 billion to US$ 10.7 billion in 2024, and is projected to grow at a compound annual growth rate (CAGR) of 4.1 to 6.6 percent through 2030. At this pace, the market is expected to reach US$ 13.05 billion to US$ 14.86 billion by 2030. Europe retained the largest market share in 2024, followed by Asia-Pacific. Key drivers shaping the excipients market include the rising prevalence of chronic diseases, expansion of biologics and biosimilars, and increasing quality and regulatory expectations. Increased investments in facility expansions and ongoing reforms in clinical trial regulations are also facilitating market growth. The sector remains highly competitive and fragmented. Major excipient providers include BASF, Roquette, Gangwal Healthcare, DuPont, Evonik, Seqens, SPI Pharma, PMC Isochem, Croda International, Pfanstiehl, Colorcon, Kewpie Corporation, ICE Pharma, Nanjing Well Pharmaceutical, Merck KGaA owned MilliporeSigma, Minakem, Ashland Global, Actylis and Nippon Fine Chemical.  View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)  Evonik in partnership with Ethris; Colorcon Ventures invests in Phytolon   The market saw strategic collaborations across the excipients and drug formulation ecosystem in Q3 2025. Evonik entered into a partnership with Ethris to strengthen its nucleic acid delivery platform. The collaboration integrates Ethris’ proprietary technology — its lipidoid nanoparticle platform, known as SNaP LNP — into Evonik’s CDMO offerings, enhancing the latter’s ability to support RNA-based therapeutics from concept to clinic. Colorcon Ventures, the investment arm of Colorcon, announced a strategic investment in Israel-based Phytolon. The biotechnology start-up uses precision fermentation to develop natural colorants. The investment underscores Colorcon’s commitment to next-generation coloring technologies that support cleaner-label formulations and innovation in oral solid dosage coatings.  View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)   Evonik launches MaxiPure Polysorbate 80; Asahi Kasei expands its portfolio The quarter saw continued innovation in high-purity and injectable-grade excipients. Evonik introduced MaxiPure Polysorbate 80, a high-purity injectable-grade surfactant designed for biologics and parenteral formulations. This excipient addresses key challenges such as protein stability, viral inactivation, and the solubilization of hydrophobic APIs, while meeting regulatory expectations across global markets. Asahi Kasei expanded its Sonanos portfolio of excipients with two new products — Sonanos PG (optimized for sustained release of biologics and peptides while supporting patient-friendly dosing)  and Sonanos DS (developed to enhance solubility of poorly water-soluble APIs). These additions reflect growing industry demand for dosage optimization, stability, and specialized delivery of complex molecules. Gangwal Healthcare operates EXCiPACT-certified GMP facilities and offers a broad range of functional excipients, including co-processed blends like ProBlend, Starlose, and Microlose. Its excipients, including Solvostar (sodium starch glycolate) and Sallyso (croscarmellose sodium), support enhanced tablet disintegration and drug release. The company also provides taste-masking agents such as SucreX (sucralose) and CutCal (neotame), supporting the development of patient-friendly oral dosage forms.  View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)   Colorcon, Gattefossé, Croda, Roquette, Clariant expand manufacturing capacities Manufacturing investments and facility expansions remained a key trend during Q3 2025. Colorcon inaugurated a new state-of-the-art, film coating manufacturing facility in Johor, Malaysia. The site incorporates energy-efficient systems and advanced production technologies to strengthen Colorcon’s functional-excipient supply network across Asia. Gattefossé opened a new lipid-based excipient facility in Texas (US), marking a strategic expansion of its North American manufacturing footprint. Croda International expanded its Leek, UK facility with a lipid system synthesis unit and enhanced R&D capabilities. The site will support the launch of Super Refined Poloxamer 188, a highly purified fast-dissolving granular excipient. Roquette announced the opening of a dedicated innovation center in São Paulo, Brazil, strengthening its engagement with regional drug developers. Clariant expanded its Daya Bay, China facility, adding a second spray tower dedicated to pharmaceutical excipient production. The upgraded site increases capacity for excipients used in laxatives and other formulations. BASF also strengthened its commitment to biopharma and pharmaceutical ingredients with a new GMP Solution Center in Michigan (US). The facility expands BASF’s network of poloxamer (a synthetic polymer) manufacturing sites. With state-of-the-art clean room packaging and high-sensitivity analytical testing, this new facility will enable close collaboration with BASF’s customers on customized chemistries for product development.  View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)   India mandates excipient disclosure; new rules to apply from March 2026  India has made it mandatory to disclose excipient details from March 2026 under the country’s new Drugs (2nd Amendment) Rules, 2025. This applies to Schedule H2 medicines. The final notification expands earlier draft requirements by mandating qualitative excipient details in QR codes on product packaging. This should enhance transparency and support patient safety. Meanwhile, US pharmaceutical groups have responded to the US Food and Drug Administration’s draft guidance proposing simplified pathways for replacing color additives in drug products. Industry associations have supported draft guidance, noting that it reduces regulatory burden while maintaining product quality and consistency.  View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)   Our view While the fast-growing generics market is creating demand for cost-effective and versatile excipients, the market is also witnessing innovations tailored to the specialized needs of biologics and biosimilars. India is poised to become a key player in the global excipient market, supported by the rapid growth in its generic drug industry, expansion of its health infrastructure and increasing investments in R&D. The new excipient-disclosure rules, therefore, are likely to benefit the global excipient industry by improving transparency and strengthening quality ecosystems.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4748

    https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-evonik-launches-high-purity-excipients-india-mandates-disclosures-from-march-2026

    #PharmaFlow by PHARMACOMPASS
    20 Nov 2025
    Share Share
    Excipient Market Overview: Roquette announces restructuring post IFF Pharma buyout; WHO, FDA advance regulatory frameworks

    Excipient Market Overview: Roquette announces restructuring post IFF Pharma buyout; WHO, FDA advance regulatory frameworks

    The pharmaceutical excipients market saw significant strategic consolidations, technological developments, and regulatory adaptations in 2025. Globally, the pharmaceutical excipients sector is growing at a compound annual growth rate of 6.6 percent, and was valued at US$ 8.85 billion in 2024. It is projected to reach US$ 14.77 billion by 2032.This year, the sector is witnessing technological advancements, regulatory evolution, and strategic business realignments. North America continues to dominate the global excipients landscape, with a 39.8 percent market share. The Asia-Pacific region is the fastest-growing segment with a substantial 30.4 percent market share, driven by increasing investments in pharmaceutical manufacturing, growing demand for cost-effective drugs, and rising healthcare expenditure across developing economies.Major excipient providers include BASF, Merck KGaA owned MilliporeSigma, Gangwal Healthcare, DuPont, Evonik, Seqens, Actylis, SPI Pharma, PMC Isochem, Croda International, Pfanstiehl, Kewpie Corporation, Boai NKY Pharmaceuticals, ICE Pharma, Roquette, Nanjing Well Pharmaceutical, Minakem, Ashland Global, Anhui Ribobay Pharmaceutical and Nippon Fine Chemical. View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)Roquette restructures after buying IFF Pharma; Colorcon partners ASHA CelluloseIn May, Roquette completed its acquisition of IFF Pharma Solutions. Valued at up to US$ 2.85 billion in enterprise value, this transaction represents a major consolidation in the pharmaceutical excipients market. The acquisition significantly enhances Roquette’s ability to deliver high-value drug delivery solutions to pharmaceutical customers worldwide. Roquette announced a comprehensive, new organizational structure following the acquisition, indicating the company’s commitment to integrate IFF Pharma Solutions’ capabilities seamlessly into its existing operations. This consolidation creates a more robust platform for addressing the growing demand for specialized excipients in complex drug formulations, particularly as the industry moves towards more personalized approaches to medicines.So far, the year has also witnessed some strategic alliances, such as Colorcon’s partnership with ASHA Cellulose. As part of the deal, Colorcon will become the exclusive representative for two ASHA products — ASHACEL and ASHAKOTE — throughout Europe, the Middle East, Africa, Northeast Asia and Southeast Asia.Brenntag Specialties has announced an exclusive distribution agreement with MEGGLE Excipients to expand market reach. This collaboration makes available a broad portfolio of over 30 high-quality lactose-based excipients for various applications in the pharmaceutical industries across the Netherlands, Belgium, Norway, Finland, and Sweden.The portfolio’s versatility offers optimal solutions for a wide range of pharmaceutical applications, including tableting through both granulation and direct compression, powder preparations, and dry powder inhalation. View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)WHO, FDA drive new standards with GMP guidelines; Pfanstiehl launches injectable-grade glycineIn March, the World Health Organization had put out a publication titled “Good Manufacturing Practices for Excipients used in Pharmaceutical Products.” WHO’s excipient GMP guideline emphasizes modern quality management principles, comprehensive risk assessment protocols, and supplier qualification procedures for excipients across all stages of production, storage, and distribution.Meanwhile, the US Food and Drug Administration (FDA) has proposed amendments to the Food, Drug, and Cosmetic Act as part of its FY 2025 legislative proposals, specifically targeting supply chain transparency for high-risk excipients. The FDA proposal would require certain excipients designated as high-risk to carry labeling that identifies the original manufacturer’s name and address. This initiative addresses what FDA has identified as a lack of transparency in excipient supply chains.In April, IFF Pharma Solutions launched Low Nitrite METHOCEL hydroxypropyl methylcellulose (HPMC). This innovative product is specifically designed to reduce the risk of nitrosamine formation in finished pharmaceutical dosages, addressing one of the most pressing concerns in contemporary pharmaceutical manufacturing.Pfanstiehl, a global leader in high-purity excipient manufacturing, announced the launch of its High Purity Low Endotoxin Low Metals (HPLE-LM) injectable-grade glycine. This multi-compendial glycine is specifically engineered for use in biologics, vaccines, and the downstream purification of monoclonal antibodies (mAbs). Manufactured under ICH-Q7 cGMP regulations at Pfanstiehl’s advanced facility in Waukegan, Illinois, the product meets stringent global pharmacopeial standards. View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)Shin-Etsu Chemical invests in Japan, Germany to expand cellulose productionIn March, Shin-Etsu Chemical announced investments in pharmaceutical cellulose business operations in Japan and Europe, thereby showing significant commitment to market expansion. The company is making substantial investments at two key bases: the subsidiary SE Tylose GmbH in Germany, and the Naoetsu Plant in Joetsu, Japan. In Germany, a new production facility for the pharmaceutical excipient L-HPC will be built adjacent to the existing facility, creating a dual base with the Naoetsu Plant. The excipients market in 2025 has seen innovation in functional applications. Research on BENEO’s Palatinose as a bedtime drink shows that it improves aspects of sleep and represents an innovative approach to excipient functionality. Palatinose is a naturally sourced, smart carbohydrate that provides full carbohydrate energy in a more balanced way, thanks to its low-glycemic profile.Gangwal Healthcare, with its EXCiPACT-certified GMP facilities and a robust portfolio of co-processed excipients like ProBlend, Starlose, and Microlose, is actively contributing to the pharmaceutical industry’s demand for functional excipients. The company also offers cellulose-based excipients such as Solvostar (Sodium Starch Glycolate) and Sallyso (Croscarmellose Sodium), designed to improve tablet disintegration and drug release profiles in oral solid dosage forms.Evonik announced a partnership with South Korea–based CDMO ST Pharm to expand its RNA and nucleic acid delivery services. This collaboration enables Evonik to integrate customized nucleic acids from ST Pharm seamlessly with its lipid and lipid nanoparticle (LNP) development and fill-and-finish services. This streamlined approach means that pharmaceutical companies can reduce complexity and increase speed-to-market for nucleic acid therapeutics. View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)Our viewThe pharmaceutical excipients market in 2025 is being shaped by several key trends including the development of multifunctional excipients that can simultaneously improve solubility, bioavailability, and control drug release in increasingly complex formulations.Moreover, the expanding generic medicines market is creating demand for cost-effective, versatile excipients. The growing importance of biologics and biosimilars is driving innovation in specialized excipients designed to maintain the stability and efficacy of these complex therapeutic products throughout their lifecycle. And nanotechnology continues to enable advanced nano-excipients for enhanced drug delivery and efficacy.In addition to these trends, we also notice a shift towards natural and plant-based excipients that is driven by sustainability concerns and potential biocompatibility benefits. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4359

    https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks

    #PharmaFlow by PHARMACOMPASS
    29 May 2025
    Share Share
    Excipient Market Overview: Roquette, Seqens, Evonik make strategic moves; new guidelines deal with contamination

    Excipient Market Overview: Roquette, Seqens, Evonik make strategic moves; new guidelines deal with contamination

    The pharmaceutical industry has long recognized the critical role excipients or inactive ingredients play in drug formulation and delivery. Excipients can comprise up to 90 percent of a medicine's total ingredients and serve crucial functions as binders, disintegrants, coatings, preservatives, colors, and flavorings. According to recent market research, the pharmaceutical excipients market was valued at US$ 9.27 billion in 2023. It is growing at a compound annual growth rate (CAGR) of 7.03 percent and is projected to reach US$ 18.48 billion by 2032. The main factors driving market growth is an increased demand for multifunctional excipients, coupled with the expanding use of generic medications. The development in the biologics sector and advancements in nanotechnology are also contributing significantly to market growth. Major excipient providers include BASF, Evonik, Merck KGaA owned MilliporeSigma, Gangwal Healthcare, Roquette Frères, DuPont, Croda International, Seqens, Boai NKY Pharmaceuticals, PMC Isochem, Minakem, Kewpie Corporation, Ashland Global, SPI Pharma, Pfanstiehl, Nanjing Well Pharmaceutical, ICE Pharma, Anhui Ribobay Pharmaceutical and Nippon Fine Chemical.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) WHO, India’s CDSCO tighten regulations; new GMP guidelines implemented to curb contamination Last year, the World Health Organization (WHO) issued a health alert linking at least 300 child deaths in the Gambia, Uzbekistan, and Indonesia to the ingestion of contaminated cough syrups containing unacceptable levels of diethylene glycol (DEG) and ethylene glycol (EG). In response to the tragic events, the WHO released two draft appendices to its guideline on good manufacturing practices (GMPs) for excipients this year. Manufacturers are now required to use suitable risk assessment tools to identify and mitigate potential hazards.  Since India-made cough syrups had been linked to the deaths, India’s drug regulator — Central Drugs Standard Control Organization (CDSCO) — took steps to prevent contamination, and advised drugmakers to only use pharmaceutical-grade excipients from approved sources. Furthermore, the Indian Health Ministry proposed amendments to the Drugs and Cosmetics Rules, 1945 to include details of excipients on drug labels. While listing all excipients on every strip of medicine may be challenging, the ministry suggested mentioning those causing hypersensitivity on the label. Applicants now mandatorily need to submit evidence of stability and safety of excipients. These regulatory developments have significant implications for excipient manufacturers and pharmaceutical companies worldwide. Leading pharmaceutical excipient firms like Gangwal Healthcare, Sigachi Industries, and Nitika Pharmaceuticals are well-positioned to meet these heightened quality and safety standards, given their long-standing commitment to producing high-quality, compliant excipients.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Roquette buys IFF’s pharma unit for US$ 2.85 bn; Evonik opens new spray-drying facility in Darmstadt In a significant industry move, France-based Roquette entered into an agreement to acquire IFF's pharma solutions business in a deal valued at US$ 2.85 billion. This acquisition is set to rebalance family-owned Roquette’s portfolio around health and nutrition. The deal is expected to accelerate Roquette’s growth and significantly strengthen its presence in the excipients market. Evonik has opened a new facility for drying aqueous dispersions of its Eudragit polymers at its site in Darmstadt, Germany. The facility will help Evonik meet increasing demand from drugmakers for its oral drug delivery solutions. The plant uses green energy solutions. The company has also partnered University of Mainz to commercialize a new class of polyethylene glycols (PEG) lipids for nucleic acid delivery. Evonik’s Health Care business has been growing its nucleic acid drug and vaccine delivery portfolio.  Germany’s Johannes Gutenberg University of Mainz was the first to develop randomized polyethylene glycols (rPEGs). This collaboration aims to expand Evonik’s toolbox of technologies for nucleic acid-based medicines, offering an improved immunogenicity profile for lipid nanoparticle carriers used in mRNA vaccines and therapeutics. Asahi Kasei made significant strides in addressing a pressing industry concern that emerged in 2018 when potentially carcinogenic nitrosamine impurities were detected in several pharmaceuticals. Guided by regional authorities, such as the European Medicines Agency and the US Food and Drug Administration, the pharmaceutical industry has been carrying out extensive assessments and research to identify the cause of these impurities. In response to this challenge, Asahi Kasei developed its Ceolus microcrystalline cellulose with extremely low nitrite levels. The Japanese company achieved nitrite concentrations of 0.1 micrograms per gram or less, which is equivalent to 0.1 parts per million (ppm). The company also started full commercial operation of its second manufacturing facility for Ceolus in Japan, enhancing supply capacity and stability. JRS Pharma and Gujarat Microwax opened a state-of-the-art cotton-based croscarmellose sodium plant in Mehsana, Gujarat (India). This facility aims to produce high-quality excipients that meet global standards, potentially reducing India's dependency on imports and boosting its presence in the global excipient market. The Indian excipient industry accounts for less than 1 percent of the global market share.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Seqens to advance innovative polymer; biologics, personalized medicine create demand for specialized excipients Recent industry collaborations highlight the ongoing innovation in novel excipients. France’s Seqens, with over 20 years of polymer development experience, was chosen by Pleryon Therapeutics to advance its leading osteoarthritis candidate – an innovative GMP polymer. This collaboration leverages Seqens’ newly expanded and modernized cGMP plant in Aramon, France, demonstrating the industry’s commitment to investing in advanced manufacturing capabilities for novel excipients.  The rise of biologics and personalized medicine has created a demand for specialized excipients capable of stabilizing complex molecules and enabling targeted drug delivery. Roquette’s launch of Lycagel Flex, a hydroxypropyl pemix for nutraceutical and pharmaceutical softgel capsules, exemplifies this trend. Built on Roquette’s market-first Lycagel pea starch technology, this plant-based alternative to gelatin offers manufacturers the flexibility to customize formulations for a range of production and end-user needs. The innovative pea starch foundation also underscores the industry’s move towards sustainable bio-based excipients. The trend towards patient-centric drug development has also influenced excipient innovation. Excipients that can improve palatability, ease of swallowing, or enable novel dosage forms (such as orally disintegrating tablets) are in high demand. For example, IFF brought a super disintegrant Ac-Di-Sol, that supports faster disintegration and drug dissolution in oral disintegrating tablets, improving patient experience.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Our view The heightened regulatory scrutiny on excipients due to product contamination incidents has created a high risk perception and uncertainty around the regulatory acceptance of novel excipients. That said, novel excipients are central to the development of new drug modalities and therapies. Going forward, sustainability will also become an increasingly important factor in excipient selection and development. As the industry innovates towards biologics, personalized therapies, and patient-centric formulations, the role of high-quality, multifunctional excipients will only grow more vital in ensuring drug stability, bioavailability, and patient compliance. Companies that can navigate the complex regulatory landscape, invest in R&D, and offer high-quality, multifunctional excipients will be well-positioned to succeed in this evolving market.   
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3594

    https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-seqens-evonik-make-strategic-moves-new-guidelines-deal-with-contamination

    #PharmaFlow by PHARMACOMPASS
    12 Sep 2024
    Share Share

    COMPANY BIO #AboutSupplier

    read-more
    read-more
    View Kewpie's pharmaceutical grade Sodium hyaluronate & browse its different grades of Hyaluronic Acid for injectables & eye drops on PharmaCompass.
    View Kewpie's pharmaceutical grade Sodium hyaluronate & browse its different grades of Hyaluronic Acid for injectables & eye drops on PharmaCompass.
    View Kewpie's pharmaceutical grade Sodium hyaluronate & browse its different grades of Hyaluronic Acid for injectables & eye drops on PharmaCompass.What is Sodium hyaluronate (Hyaluronic acid) and what are its properties?Sodium hyaluronate...
    #LearnMore
    July, 2023
    Share Share
    View Kewpie's pharmaceutical grade Sodium hyaluronate & browse its different grades of Hyaluronic Acid for injectables & eye drops on PharmaCompass.

    View Kewpie's pharmaceutical grade Sodium hyaluronate & browse its different grades of Hyaluronic Acid for injectables & eye drops on PharmaCompass.

    View Kewpie's pharmaceutical grade Sodium hyaluronate & browse its different grades of Hyaluronic Acid for injectables & eye drops on PharmaCompass.What is Sodium hyaluronate (Hyaluronic acid) and what are its properties?Sodium hyaluronate is the sodium salt of Hyaluronic acid (HA) which is a mucopolysaccharide made up of glucuronic acid and N-acetylglucosamine. Hyaluronic acid is distributed throughout the body, such as in the human skin (high concentrations are found in the epidermis/dermis), synovial fluid, and the vitreous body of the eyes.Hyaluronic acid is also known by several other names, such as HA, hyaluronan, hyaluronate, and Sodium hyaluronate. The molecular weight of Sodium hyaluronate is lower than the molecular weight of HA. It is, however, small enough to penetrate the epidermis, or top layer of skin, to improve hydration from the underlying skin layers, resulting in a greater hydrating effect.Hyaluronic acid is an elastoviscous fluid composed of hylan polymers, which are derivatives of hyaluronan, a naturally occurring complex sugar. The physiological functions of Hyaluronic acid include anti-aging, wound healing, protection against infection, and collagen fiber biosynthesis.The sources of Hyaluronic acid include bovine tracheas, bovine vitreous, rooster combs, and plants. Industrial production of Hyaluronic acid is based on either its extraction from animal tissues or large-scale lactic acid bacterial fermentation with genetically engineered strains. Plant-based HA is extracted from microbial fermentation in addition to animal-based Hyaluronic acid.A majority of the industries use Hyaluronic acid supplements for joint diseases, particularly inflammation. Sodium hyaluronate is used to alleviate knee pain in patients with osteoarthritis who have not found relief from other treatments. Hyaluronan is found in higher concentrations in synovial tissue and fluid, along with other soft connective tissues. Sodium hyaluronate also plays a key role in cell proliferation, cell migration, matrix assembly, and tissue development, and may also be involved in the advancement of some malignant tumors.Hyaluronic acid comes in five different sizes and molecular weights that permeate various layers of the skin. Because molecules with lower molecular weight are smaller, they can reach deeper layers of the skin. Hyaluronic acid’s molecular weight is significantly dependent on its source; however, refinement of the isolation procedures has resulted in the commercial availability of a wide range of molecular weight grades.The physical properties of Sodium hyaluronate are mentioned below:Purified Sodium hyaluronate is a white powder with no taste or aroma.The molecular weight of the Sodium hyaluronate molecule is around 4,000 to 80,00,000 Daltons.Sodium hyaluronate has high solubility and viscosity.It provides excellent moisture-holding ability and elasticity, as well as a lubricating effect.Sodium hyaluronate is compatible with biological systems.It degrades with heat, enzymes, etc. but can be stabilized by crosslinking.It is stored as a dry powder at 5°C and as a solution at -20°C or lower.Sodium hyaluronate is photosensitive and moisture sensitive, so it should be kept away from light and humidity.Based on its degree of penetration, HA can be classified into high molecular weight Hyaluronic acid (HMW HA) > 18,00,000, middle molecular weight Hyaluronic acid (MMW HA) 10,00,000 - 18,00,000, low molecular weight Hyaluronic acid (LMW HA) 4,00,000 - 10,00,000, small molecular weight Hyaluronic acid: 1,00,000 - 4,00,000 and extra small molecular weight Hyaluronic acid: < 100,000.The high molecular weight Hyaluronic acid moisturizes the surface of the skin, protects the skin’s barrier, and improves its elasticity. It also contains anti-inflammatory properties that can help soothe sensitive or irritated skin. Low molecular weight Hyaluronic acid, on the other hand, can more easily penetrate the skin and is most effective in reducing wrinkles. In addition, topical low molecular weight HA can be used as an alternative to treat facial seborrheic dermatitis.What are the different applications of Sodium hyaluronate in the pharmaceutical and cosmetic industries?Hyaluronic acid is a naturally occurring polysaccharide biopolymer. It is involved in a variety of biological processes including tissue hydration and structural scaffolding. Sodium hyaluronate is increasingly being used as a reagent in pharmaceutical, bioengineering, and medical applications. Exogenous Sodium hyaluronate has been investigated as a drug delivery system for treating cancer, ophthalmology, arthrology, pneumology, rhinology, urology, aesthetic medicine as well as in the cosmetics industry.Sodium hyaluronate is used in numerous pharmaceutical and cosmeceutical applications which include:Drug Delivery Systems: Hyaluronan is biocompatible, viscoelastic, and non-immunogenic. These Sodium hyaluronate characteristics have several medical applications in drug delivery for ophthalmic, nasal, pulmonary, parenteral, and dermal routes.Scaffolds for Tissue Engineering: As a component of the extracellular matrix (ECM), Sodium hyaluronate is responsible for various structural properties of tissues and is involved in cellular signaling. Scaffolds made of Sodium hyaluronate are employed in bone tissue, space-filling, nerve, and brain tissue repair, as well as cell delivery, cell adhesion, and muscle regeneration.Adjuvant to Anticancer Drugs: Medical applications of Hyaluronic acid include its use in the delivery of anticancer drugs because of its superior biocompatibility, biodegradability, and precise targeting of cancer cells.Intra-Articular Injection: Sodium hyaluronate is taken as a supplement alone or in conjunction with collagen, vitamins, chondroitin sulphate, or glucosamine for joint-related problems as well as for the treatment of osteoarthritis. Hyaluronic acid binds efficiently to water, forming a viscous fluid that serves as a lubricant and a shock absorber within the joint. It also helps to increase bone density, mobility, and strength.Ophthalmic Viscosurgical Devices: Ophthalmic grade Sodium hyaluronate is commonly used in viscosurgical devices (OVDs), which are essential in ophthalmic surgeries like cataract extraction, cornea transplantation, glaucoma, intraocular lens (IOL) implantation and vitreoretinal surgery. Sodium hyaluronate is a naturally occurring component of the eye’s vitreous humor and is entirely biocompatible.Eye Moisture Retention: Sodium hyaluronate eye drops can alleviate dry eye symptoms by boosting tear production and stabilizing the corneal surface. Eye drops with high-molecular-weight Hyaluronic acid have anti-inflammatory properties.Wound Healing: In topical preparations, Sodium hyaluronate is used to protect skin ulcers, burns, or wounds from irritation, allowing the skin to heal properly. Hyaluronic acid works to heal wounds by producing the granulation tissue required for wound repair.Skin Benefits of Sodium Hyaluronate: Hyaluronic acid can retain moisture in the extracellular matrix formed in the gaps between cells. Its topical treatment hydrates the skin and keeps it hydrated as a humectant. Sodium hyaluronate is used in anti-aging preparations to help minimize the skin roughness, considerably reduce wrinkle depth and improve skin firmness and elasticity.Dermal Fillers: Hyaluronic acid injections can be used to improve the skin's contour and decrease depressions caused by scars, injuries, or lines. Dermal fillers containing Sodium hyaluronate have been used to treat wrinkles, nasolabial folds, and fine lines around the mouth, lips, cheeks, chin, etc.Furthermore, Hyaluronic acid promotes cell proliferation, cell differentiation, and immunosuppression, and is a component of submucosal injection and resorbable adhesion barriers.In addition, high molecular weight Sodium hyaluronate forms a moisture protecting film at the surface of the skin, helps the skin to hold moisture, inhibits bacterial growth, and reduces UVB-induced apoptosis and inflammation in human epithelial corneal cells. Middle molecular weight Hyaluronic acid helps tighten the skin and keep it moisturized for a long time.Low molecular weight Hyaluronic acid, on the other hand, is smaller, penetrates deeper into the dermis, moderately dilates capillaries, increases blood circulation, and ensures that water is stored in the connective tissue of the skin, making skin firmer and reduces visible wrinkles.How is Kewpie considered a pioneer in the pharmaceutical industry for manufacturing Sodium hyaluronate?Kewpie is a leading Japanese pharmaceutical grade Sodium hyaluronate manufacturer and supplier. It manufactures Hyaluronic acid which is used as an API and a pharmaceutical excipient. It created the first Sodium hyaluronate from chicken comb.Since 1983, Kewpie has been a pioneer Hyaluronic acid manufacturer and supplier. Its R&D team can develop Sodium hyaluronate derivatives to meet the needs of the clients. Kewpie extracts and refines different active ingredients for foods, cosmetics, and pharmaceuticals at its fine chemicals division. It has been developing and manufacturing medical devices using Sodium hyaluronate since 2016.Kewpie is one of the leading Sodium hyaluronate suppliers, exporting Sodium hyaluronate to more than 30 countries. It is a prominent pharmaceutical grade Sodium hyaluronate manufacturer in Japan and can meet the clients’ requirements for tailor-made derivatives. To assure the supply of safe products, Kewpie’s production and quality control (QC) systems are based on Good Manufacturing Practice (GMP). It follows procedures and conducts quality testing at every stage, from receiving raw materials to manufacturing and shipping, and has developed control systems to ensure quality.Kewpie is a leading Sodium hyaluronate producer, offering pharma grade, medical grade, ophthalmic grade, and cosmetic grade Sodium hyaluronate with molecular weights ranging from 800 Da to 35,00,000 Da. It can meet the specific needs of the clients by adjusting the molecular weight. Kewpie not only offers products of biofermentation origin, but it also has natural products, thanks to its advanced extraction and refining technology.Kewpie provides custom-made Sodium hyaluronate derivatives by binding other functional compounds to Sodium hyaluronate, which can acquire new functions and physical characteristics. Kewpie promotes the timely development of products with technical support from R&D experts and regulatory support.Kewpie offers high-quality pharmaceutical grade Sodium hyaluronate. It can produce highly pure and stable products that can maintain the safety and efficacy of the final drug by using its manufacturing knowledge.Kewpie offers ophthalmic grade, pharma grade as well as food, cosmetic and medical grade Sodium hyaluronate. Its Sodium hyaluronate is good for injections, eye drops (ophthalmic solutions), pharmaceuticals, external preparations, and medical formulations.Production of Hyaluronic acid at Kewpie’s facility occurs through two methods - microbial fermentation and extraction from chicken comb. Kewpie has completed several Hyaluronic acid R&D projects since 1983. Kewpie is a leading producer of Hyaluronic acid. It has the technology to control the molecular weight of Sodium hyaluronate to produce it according to customers' needs.Various products developed and offered by Kewpie include Hyabest®(A), Hyabest®(J), Hyabest® (S) LF-P, Hyalo-Oligo®, Hyaloveil®-P, Hyalorepair®, and HAbooster™ which are mentioned in detail below:- Hyabest®(A): It is a low-molecular weight Hyaluronic acid with anti-inflammatory and other properties.- Hyabest®(J): It is an injectable Hyaluronic acid that works on joints.- Hyabest® (S) LF-P: It is an edible version of Hyaluronic acid that is effective against skin damage from ultraviolet radiation. So, it acts as an anti-aging substance.- Hyalo-Oligo®: It has a different moisture retention mechanism from other products. So, it is used in parallel with conventional products.- Hyaloveil®-P: It acts as an adsorbent of Hyaluronic acid for hair and skin and continues to retain moisture.- Hyalorepair®: It is a blend of oil with Hyaluronic acid. It restores the barrier function, preserves skin moisture, and repairs rough skin.- HAbooster™: In addition to the functionality of conventional Hyaluronic acid in retaining skin moisture, it acts to promote collagen metabolization.Kewpie is a pioneer Sodium hyaluronate producer. It produces its products in accordance with Good Manufacturing Practices. It is also one of the leading Sodium hyaluronate suppliers in the world.What are the different grades of Sodium hyaluronate (Hyaluronic acid) offered by Kewpie?Kewpie is a Hyaluronic acid manufacturer and supplier that has been in research for more than 30 years. Kewpie offers safe to use pharma grade, cosmetic grade, food grade, and medical grade Sodium hyaluronate.Pharmaceutical Grade Hyaluronic AcidKewpie is a pharmaceutical grade Sodium hyaluronate manufacturer, which produces various Sodium hyaluronate grades, including injectable grade and ophthalmic grade HA at its manufacturing facility near Tokyo. It is a producer of Hyaluronic acid for eye drops, injections, as well as external preparations.Kewpie manufactures purified Sodium hyaluronate as hyaluronsan HA-AML and hyaluronsan HA-SHL. These are usually used in pharmaceuticals like auxiliary agents for eye surgery and therapeutic agents for osteoarthritis of the knee joint.Kewpie provides various injectable and medical grade Sodium hyaluronate products in powder form, including HA-AML, HA-SHL, HA-AM, and HA-QSE.- Hyaluronsan HA-AML: It is purified Sodium hyaluronate that has an average molecular weight of 500 - 1,200 (kDa) and is obtained via the biofermentation method. It has registered and certified GMP, CEP, and DMF in Japan, the USA, China, and Korea.- Hyaluronsan HA-SHL: It is also a purified Sodium hyaluronate with an average molecular weight of 1,500 - 3,900 (kDa) and is obtained via biofermentation method. It has registered and certified GMP, CEP, and DMF in Japan, the USA, and China.- Hyaluronsan HA-AM: It is obtained via the chicken comb method and has an average molecular weight of 600 - 1,200 (kDa). It has registered and certified GMP and DMF in Japan, the USA, China, and Korea.- Hyaluronsan HA-QSE: It is also obtained via the chicken comb method and has an average molecular weight of 1,900 - 3,900 (kDa). It has registered and certified GMP and DMF in Japan and Korea.Cosmetics Grade Hyaluronic AcidKewpie, a leading producer of Hyaluronic acid, uses Hyaluronic acid products to improve skin problems. Kewpie’s Hyaluronic acid powder series hyaluronsan HA−LQ and hyaluronsan HA−LQH are produced using the microbial fermentation method. These products have higher water and moisture retention qualities and can help in preventing dryness of the skin and hair.Cosmetics Grade Functional Hyaluronic AcidKewpie is a Sodium hyaluronate producer and a leading global functional ingredient Sodium hyaluronate supplier. Kewpie’s functional Hyaluronic acid is not an ordinary humectant. In addition to the high water retention and moisturization qualities that general Hyaluronic acid has, Kewpie adds new functions through its unique technologies.Kewpie’s functional Hyaluronic acids are scientifically proven to cater to client’s specific needs and use. Kewpie’s functional Hyaluronic acids can help in having healthy and vibrant skin. Functional Hyaluronic acids include HAbooster™, Hyalo-Oligo®, Hyaloveil®-P, and Hyalorepair®.- HAbooster™: It is a very low-molecular weight Sodium hyaluronate. It promotes the collagen cycle, increases skin moisture, and improves crow’s feet and nasolabial folds. Its topical application enters the upper layer of the epidermis of the skin and promotes collagen metabolism to improve wrinkles and sagging.- Hyalo-Oligo®: It not only covers the skin’s surface but penetrates deep into the horny layer and contributes moisture to the skin. Conventional Hyaluronic acid remains on the skin's surface and is easy to wash off. However, Kewpie’s Hyalo-Oligo® increases the amount of moisture in the skin twofold. Even after washing the face, the moisture retention capability of Hyaluronic acid remains.- Hyalorepair®: It is an alkylated low-molecular weight Hyaluronic acid that has barrier function recovery with both hydrophobic and hydrophilic aspects for skin care. Its Hyalorepair® suppresses skin’s water evaporation.- Hyaloveil®-P: It is a high molecular weight Sodium hyaluronate that has been cationized, has an adhesive and coating effect, and veils skin and hair moisture.Food and Nutraceutical Grade Hyaluronic AcidKewpie is a Hyaluronic acid manufacturer and supplier that provides assurance regarding the safety of its Sodium hyaluronate. The production of Hyaluronic acid at Kewpie occurs through the extraction of chicken comb and microbial fermentation methods through its quality assurance system. Its nutraceutical grade Hyaluronic acid includes Hyabest®(A), Hyabest®(J), Hyabest(S)LF-P, and Hyabest®(S)LF5-A.- Hyabest®(A): It is Sodium hyaluronate produced using proprietary technology. Hyabest®(A) acts physiologically to relieve skin inflammation.- Hyabest®(J): It is the world's first Hyaluronic acid,  which when taken orally, has been proven to be efficacious for knee joint pains.- Hyabest(S)LF-P: It is highly pure Sodium hyaluronate and is used for dietary supplements. Sodium hyaluronate helps retain moisture in the skin and helps avoid dryness.- Hyabest®(S)LF5-A: It is Hyaluronic acid that is produced using the fermentation method, and then purified to get high-purity compounds. It can be used for mixing with beverages to provide high moisture retention.

    Impressions: 4623

    NEWS #PharmaBuzz

    read-more
    read-more
    Notice of the Progress of Acquisition by Company of its Own Share
    Notice of the Progress of Acquisition by Company of its Own Share

    02 Dec 2025

    // PRESS RELEASE

    https://www.kewpie.com/en/ir/pdf/news/2025/251202_Notice_of_the_Progress_of_Acquisition_by_the_Company_of_its_Own_Shares.pdf

    PRESS RELEASE
    02 Dec 2025
    Share Share
    Notice of Purchase of Fractional Shares by the Company
    Notice of Purchase of Fractional Shares by the Company

    27 Nov 2025

    // PRESS RELEASE

    https://www.kewpie.com/en/ir/pdf/news/2025/Notice_of_Purchase_of_Fractional_Shares_by_the_Company_in_connection_with_the_Share_Exchange_Reorganization.pdf

    PRESS RELEASE
    27 Nov 2025
    Share Share
    Notice regarding Revision of the Forecasts FY Ending Nov 30 2025
    Notice regarding Revision of the Forecasts FY Ending Nov 30 2025

    02 Oct 2025

    // PRESS RELEASE

    https://www.kewpie.com/en/ir/pdf/news/2025/Notice_regarding_Revision_of_the_Forecasts_of_Consolidated_Operating_Results_for_the_Fiscal_Year_Ending_November_30_2025.pdf

    PRESS RELEASE
    02 Oct 2025
    Share Share
    Supplementary Data for the First Nine Months of the Fiscal Year
    Supplementary Data for the First Nine Months of the Fiscal Year

    02 Oct 2025

    // PRESS RELEASE

    https://www.kewpie.com/en/ir/pdf/accounts/2025/Supplementary_Data_for_the_First_Nine_Months_of_the_Fiscal_Year_Ending_November_30_2025.pdf

    PRESS RELEASE
    02 Oct 2025
    Share Share
    Summary of Consolidated Financial Statements for Nine Month
    Summary of Consolidated Financial Statements for Nine Month

    02 Oct 2025

    // PRESS RELEASE

    https://www.kewpie.com/en/ir/pdf/accounts/2025/Summary_of_Consolidated_Financial_Statements_for_the_First_Nine_Months_of_the_Fiscal_Year_Ending_November_30_2025_JAPAN_GAAP.pdf

    PRESS RELEASE
    02 Oct 2025
    Share Share
    Kewpie Integrated Report 2025
    Kewpie Integrated Report 2025

    24 Jul 2025

    // PRESS RELEASE

    https://www.kewpie.com/en/ir/pdf/integrated-report/Integrated_Report_2025.pdf

    PRESS RELEASE
    24 Jul 2025
    Share Share

    KEY PRODUCTS

    read-more
    read-more
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Excipients

    Discover the DDS // excipients from this company

    Excipients by Ingredients

    Discover their expertise by components

    Excipients By applications

    Discover their expertise by claims

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Kewpie Corporation and get a quotation

    Kewpie Corporation is a supplier offers 5 products (APIs, Excipients or Intermediates).

    Find a price of Sodium Hyaluronate bulk with DMF, CEP, JDMF offered by Kewpie Corporation

    Find a price of Sodium Hyaluronate bulk with DMF, JDMF offered by Kewpie Corporation

    Find a price of Hyaluronic Acid bulk with JDMF offered by Kewpie Corporation

    Find a price of Sodium Hyaluronate bulk with JDMF offered by Kewpie Corporation

    Find a price of Sodium Hyaluronate bulk offered by Kewpie Corporation

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search